Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CM1G | ISIN: US95075A1079 | Ticker-Symbol:
NASDAQ
01.04.25
21:15 Uhr
0,900 US-Dollar
-0,075
-7,69 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
WEREWOLF THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
WEREWOLF THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur WEREWOLF THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
WEREWOLF THERAPEUTICS Aktie jetzt für 0€ handeln
13.03.Werewolf Therapeutics' (HOWL) Outperform Rating Reiterated at Wedbush4
11.03.Werewolf Therapeutics GAAP EPS of -$0.463
11.03.Werewolf Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
11.03.Werewolf Therapeutics, Inc. - 10-K, Annual Report2
11.03.Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update357- Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half...
► Artikel lesen
11.03.Werewolf Therapeutics, Inc. - 8-K, Current Report1
24.02.Werewolf Therapeutics, Inc.: Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors2
24.02.Werewolf Therapeutics, Inc. - 8-K, Current Report-
13.01.Werewolf Therapeutics, Inc.: Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook141- Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways - - Data...
► Artikel lesen
08.11.24Werewolf Therapeutics GAAP EPS of -$0.38 beats by $0.073
07.11.24Werewolf Therapeutics meldet vielversprechende Studiendaten für Krebsmedikament5
07.11.24Werewolf Therapeutics reports promising trial data for cancer drug1
07.11.24Werewolf Therapeutics, Inc.: Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting154- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals - - Additional...
► Artikel lesen
07.11.24Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update158- Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting - - Monotherapy and combination expansion...
► Artikel lesen
07.11.24Werewolf Therapeutics, Inc. - 10-Q, Quarterly Report-
07.11.24Werewolf Therapeutics, Inc. - 8-K, Current Report-
31.10.24Werewolf Therapeutics, Inc.: Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE Molecule for Inflammatory Diseases172WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
► Artikel lesen
04.10.24Werewolf Therapeutics, Inc.: Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting12
08.08.24Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update494- Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting - - Encouraging signs of clinical activity at tolerable...
► Artikel lesen
25.06.24Werewolf Therapeutics, Inc.: Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma194- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1